1- Will annouce a partner ship in china for dpccheck this quarter
2- Will need to raise cash (my guess has always been $5M warrants and additional 2 million shares hopefully around $5, or sell DPNcheck internatioal rights)
3- Patient feedback for early SENSUS users has been very positive
4- OTC for SENSUS early 2015
5- Electrodes go bad 2 weeks after opening the box (Medicare pays $30 a month for it).
6- High margin on electrodes for SENSUS.
7- Low margin on device (10% to 30% through DME, 60$ through retail)
8- Recurring Money for SENSUS is in electrodes
PIPES exist.. 2 exist already.. they have gone to the well twice to keep this afloat..
and they are still having CASH burn with not enough cash for 2014 or 2013, yet they still pay MASSIVE salaries to the top 4 in this company.
WHY don't they set them up on OPTIONS with strike prices if its going to be so MASSIVE a deployment.
Medical Devices are going to be TAXED in the current AHC act,,, that includes Sensus..
What do they sell that fixes the neuropathy= NOTHING all they can do is give you a measure of it.. What good is that... checking BP with no medication or treatment is a non repetitive exercise in futility.
Patients don't need a number for sensitivity in their feet they need something that will correct the problem. None of NURO products do anything to correct the problem of neuropathy..